Molbio Diagnostics Eyes ₹940 Crore Through IPO for Expansion and Promoter Stake Sale

Molbio Diagnostics, a prominent player in the molecular diagnostics sector, is gearing up for a significant financial move by launching an initial public offering (IPO) aimed at raising ₹940 crore. The company intends to allocate ₹200 crore from the fresh issue towards capital expenditures, while the remaining ₹740 crore will be generated through an offer for sale, effectively reducing the promoter group's stake from 46.6% to 43%.

Expanding Global Reach and Product Portfolio

Established in 2000, Molbio Diagnostics has carved a niche in the diagnostics industry with its innovative solutions, particularly in tuberculosis testing. The company operates six manufacturing facilities across India and serves a global clientele spanning over 90 countries. Its flagship product, the 'Truenat' platform, is designed for rapid diagnostics in resource-limited settings, capable of delivering results within an hour. This platform supports over 30 diseases through 43 diagnostic assays.

Government and international aid agencies contribute significantly to Molbio's revenue, accounting for over 80%. The company's top clients, including government health programs and international healthcare organizations, provide more than half of its revenue, highlighting a concentration risk but also underscoring its strong market position.

Financial Performance and Market Valuation

Molbio has demonstrated robust financial growth, with revenue from operations increasing by 31.5% annually to ₹1,445.7 crore from FY24 to FY26. During the same period, net profit rose by 40.2% to ₹164.1 crore, and EBITDA improved by 33.2% to ₹328.2 crore, with a margin increase from 22% to 22.6%. In FY26 alone, the company witnessed a 41.7% surge in revenue, a 27.9% rise in EBITDA, and an 18.4% growth in net profit.

The proposed IPO values the company with a price-earnings (P/E) multiple of up to 57, positioning it competitively against other healthcare diagnostics and medical device firms in India, such as Poly Medicure and Dr. Lal PathLabs, which trade at P/E multiples between 54 and 81.

Investment Considerations for High-Risk Investors

For investors with a high-risk appetite, Molbio Diagnostics' IPO offers a potential opportunity for long-term growth. The company's strong financial performance, expansive global reach, and innovative product offerings present compelling reasons to consider investment. However, the concentration of revenue from a few major clients and the high valuation relative to peers are factors that warrant careful consideration.

As Molbio Diagnostics continues to expand its footprint and enhance its product offerings, the upcoming IPO could be a pivotal step in its growth trajectory, appealing to investors seeking exposure to the burgeoning diagnostics market.